GENETIC STRATEGIES FOR DRUG TARGETING

小企业创新研究第二阶段项目旨在 研究开发新的生物系统的使用， 在转化细胞中表达共同标记基因以控制生长 以及活组织中细胞的特性。在我们成功的基础上， 在第一阶段的努力中，拟议的研究将提供突破性进展， 需要推进重组基因的新的有前途的医疗用途。 在 I期，Marker Gene Technologies，Inc.建立了可行性 该工艺通过制备新的半乳糖苷和头孢菌素， 常见的生长调节剂、药物和酶抑制剂的缀合物， 施用至动物细胞或细菌，所述动物细胞或细菌含有β- 半乳糖苷酶（lac Z）或氨苄青霉素耐药（β-内酰胺酶，amp） 基因作为基因融合标记。这些新的缀合物利用这些融合 转化细胞中影响药物输送和控制的系统 选择生物学特性。 在第二阶段，新的生物系统将在体内实施， 它们对细胞生长产生特异性和局部影响的能力， 以细胞或组织特异性方式递送活化药物。 在 特别地，缀合物将进一步在显著的环境中测试。 基因和免疫治疗的医学领域， 疾病治疗。 拟定商业应用： 这个项目的成功开辟了巨大的商业可能性 在遗传病、基因和遗传病的医疗干预领域， 癌症免疫治疗，新的生物技术生产 细胞培养系统中的蛋白质和药物，以及细菌筛选 战略布局 此外，它还提供新的信息和技术， 用于基础细胞生物学研究。

This Small Business Innovation Research Phase II project aims to investigate the use of developing new biological systems employing common marker gene expression in transformed cells to control the growth and character of cells in living tissue. Building on our successes in the Phase I effort, the proposed research will provide breakthroughs needed to advance new promising medical uses of recombinant genes. In Phase I, Marker Gene Technologies, Inc. established the feasibility of this technology by preparing new galactoside and Cephalosporin conjugates of common growth regulators, drugs and enzyme inhibitors, for administration to animal cells or bacteria that contain either the beta- galactosidase (lac Z) or ampicillin resistance (beta-lactamase, amp) genes as gene fusion markers. These new conjugates utilized these fusion systems in transformed cells to affect drug delivery and control selected biological properties. In Phase II, the new biological systems will be implemented in vivo for their ability to cause specific and localized effects on cell growth and to deliver activated drugs in a cell- or tissue-specific manner. In particular, the conjugates will be further tested in the significant medical areas of gene and immuno-therapy for cancer and proliferative diseases treatment. PROPOSED COMMERCIAL APPLICATION: The success of this project opens up enormous commercial possibilities in the fields of medical intervention in genetic diseases, gene and immuno- therapy for cancer treatment, biotechnological production of new proteins and drugs in cell-culture systems, and bacterial screening strategies. In addition, it contributes new information and techniques for basic cell-biology research.